Entries by Ayal Ronen

ARPA-H: What R&D will be funded by the “DARPA for Health”?

President Biden called on Congress to fund the creation of a new agency, a DARPA for Health. Some breakthrough ideas don’t receive sufficient attention because they are too high-risk, high-cost, or long-term, because they don’t fit well into academia or the commercial sector, or because they require complex collaborations. The Advanced Research Projects Agency for Health (ARPA-H) aims to support promising opportunities which concern health but which fall in that gap. ARPA-H will not have intramural labs. It will facilitate research directed at solving practical problems. To date, the kinds of non-dilutive funding opportunities which will be available through ARPA-H (grants, contracts, etc.) have not been defined, but we can make intelligent guesses.

/by

Bio-Europe Spring, March 28–31, 2022 (online)

Bio-Europe Spring is the most international biopharma industry gathering this spring. Delivered virtually, March 28-31, 2022, with over 2,700 assets posted, 60% biopharma attendance, 50+ countries expected to attend, and 1:1 meetings via the partneringONE® system.

/by

Neuroscience Innovation Forum, March 2022

The 5th Annual Neuroscience Innovation Forum (NIF) will take place on the 22nd – 23rd of March 2022, with 1:1 meetings 21st – 25th of March during which the online meeting system open for 12 hours a day.

The main programme for the 5th Annual NIF will be spread throughout 2 days. Featuring more than 12 hours of high-level keynotes, panel discussions, and spotlight showcases. The target audience for this event are buy and sell-side analysts from investment banks and funds, as well as partnering executives from pharma, biotech, digital therapeutics and neurotech companies. We anticipate 300+ delegates and 35+ company presentations by established listed, private and growth companies.

/by

RESI Digital, March 2022

The Redefining Early Stage Investments (RESI) conference series connects start-ups and early-stage investors and strategic channel partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics and digital health (4 Ds). RESI caters to both the earliest stage start-ups, those seeking grants, seed and angel capital, and the early-stage firms who seek series A and B funding. RESI is a unique and powerful tool for sourcing assets and advancing innovation across early-stage life science and healthcare.

/by

RNA Leaders World Congress 2022

RNA medicines are at a critical moment in time. mRNA vaccines dominate the headlines in the wake of the COVID-19 pandemic. But huge advances are also being made in all aspects of RNA technology. Join us, and more than 300 biotech, pharmaceutical, investment, regulatory and scientific professionals at the RNA Leaders World Congress. You’ll hear the latest advances in RNA chemistry, get clinical updates from the companies developing new therapies and source the services partners who are helping to deliver drugs to patients.

/by

The 15th​ Annual European Life Sciences CEO Forum

The 15th Annual European Life Sciences CEO Forum (ELSF) will take place on the 1st-2nd of March 2022, online. It will be part of the digital Sachs Spring Life Sciences Week, that will also incorporate the 3rd Annual European HealthTech CEO Forum. ELSF will address main challenges for 2022: investment, partnering, and alliance management. Virtual 1:1 meetings will take place from February 28 through March 4.

/by

European Healthcare CEO Forum

The 3rd annual European HealthTech CEO Forum (EHTF), will take place on the 28th of February 2022 and will be part of the Sachs Spring Life Sciences Week (SSLSW). EHTF will focus on investment and partnership in MedTech and Digital Health. The programme will feature topical keynotes and panels with industry leaders as well as around 20 corporate presentations by public, private and growth companies. 200+ delegates are anticipated, including major and growth corporates, financial investors/partners, bankers and advisors.

/by